-
1 Comment
Charles River Laboratories International, Inc is currently in a long term uptrend where the price is trading 32.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.2.
Charles River Laboratories International, Inc's total revenue rose by 14.4% to $791M since the same quarter in the previous year.
Its net income has increased by 79.8% to $144M since the same quarter in the previous year.
Finally, its free cash flow fell by 4.5% to $112M since the same quarter in the previous year.
Based on the above factors, Charles River Laboratories International, Inc gets an overall score of 4/5.
ISIN | US1598641074 |
---|---|
Sector | Healthcare |
Industry | Diagnostics & Research |
CurrencyCode | USD |
Exchange | NYSE |
Market Cap | 10B |
---|---|
Beta | 1.36 |
PE Ratio | 20.92 |
Target Price | 252.58 |
Dividend Yield | 0.0% |
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CRL using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024